Insider Selling: BeiGene, Ltd. (NASDAQ:BGNE) CEO Sells $445,068.62 in Stock

BeiGene, Ltd. (NASDAQ:BGNE) CEO John Oyler sold 2,789 shares of the firm’s stock in a transaction on Monday, June 24th. The shares were sold at an average price of $159.58, for a total value of $445,068.62. The sale was disclosed in a document filed with the SEC, which is available through the SEC website.

John Oyler also recently made the following trade(s):

• On Wednesday, April 10th, John Oyler sold 26,716 shares of BeiGene stock. The shares were sold at an average price of $148.89, for a total value of $3,977,745.24.

BeiGene Trading Down 2.0 %

NASDAQ:BGNE opened at $142.67 on Friday. The company has a quick ratio of 1.84, a current ratio of 2.08 and a debt-to-equity ratio of 0.06. BeiGene, Ltd. has a 1-year low of $126.97 and a 1-year high of $225.23. The firm has a market capitalization of $13.67 billion, a price-to-earnings ratio of -18.85 and a beta of 0.60. The stock has a fifty day simple moving average of $156.93 and a 200 day simple moving average of $159.87.

BeiGene (NASDAQ:BGNE) last released its quarterly earnings results on Wednesday, May 8th. The company reported ($2.41) earnings per share for the quarter, beating analysts’ consensus estimates of ($3.07) by $0.66. BeiGene had a negative return on equity of 21.70% and a negative net margin of 28.39%. The business had revenue of $751.70 million during the quarter, compared to analyst estimates of $670.09 million. During the same quarter last year, the company posted ($3.34) EPS. BeiGene’s revenue for the quarter was up 67.9% on a year-over-year basis. Sell-side analysts forecast that BeiGene, Ltd. will post -8.2 earnings per share for the current year.

Institutional Investors Weigh In On BeiGene

A number of institutional investors have recently bought and sold shares of BGNE. Capital International Investors boosted its position in BeiGene by 11.5% during the 1st quarter. Capital International Investors now owns 7,064,428 shares of the company’s stock worth $1,104,806,000 after acquiring an additional 727,556 shares during the period. First Trust Advisors LP acquired a new stake in BeiGene during the 4th quarter worth about $39,632,000. M&G Plc acquired a new stake in BeiGene during the 1st quarter worth about $29,649,000. Goldman Sachs Group Inc. boosted its position in BeiGene by 175.2% during the 4th quarter. Goldman Sachs Group Inc. now owns 214,339 shares of the company’s stock worth $38,658,000 after acquiring an additional 136,458 shares during the period. Finally, Price T Rowe Associates Inc. MD boosted its position in BeiGene by 6.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,026,094 shares of the company’s stock worth $316,862,000 after acquiring an additional 117,905 shares during the period. 48.55% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have recently commented on the company. TD Cowen raised their price target on BeiGene from $236.00 to $254.00 and gave the company a “buy” rating in a report on Thursday, May 9th. JPMorgan Chase & Co. raised their price target on BeiGene from $184.00 to $186.00 and gave the company an “overweight” rating in a report on Tuesday, March 19th. Sanford C. Bernstein lowered their price target on BeiGene from $196.00 to $161.00 and set a “market perform” rating on the stock in a report on Wednesday, March 27th. Finally, Bank of America lowered their target price on BeiGene from $179.30 to $164.30 and set a “neutral” rating on the stock in a report on Monday, April 8th. Three research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $251.93.

About BeiGene

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.